KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Adaptive Biotechnologies (ADPT) Operating Expenses: 2017-2024

Historic Operating Expenses for Adaptive Biotechnologies (ADPT) over the last 8 years, with Dec 2024 value amounting to $341.5 million.

  • Adaptive Biotechnologies' Operating Expenses rose 5.84% to $83.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $330.9 million, marking a year-over-year decrease of 12.23%. This contributed to the annual value of $341.5 million for FY2024, which is 14.05% down from last year.
  • According to the latest figures from FY2024, Adaptive Biotechnologies' Operating Expenses is $341.5 million, which was down 14.05% from $397.3 million recorded in FY2023.
  • Over the past 5 years, Adaptive Biotechnologies' Operating Expenses peaked at $397.3 million during FY2023, and registered a low of $251.2 million during FY2020.
  • Over the past 3 years, Adaptive Biotechnologies' median Operating Expenses value was $385.5 million (recorded in 2022), while the average stood at $374.8 million.
  • Its Operating Expenses has fluctuated over the past 5 years, first skyrocketed by 53.67% in 2020, then fell by 14.05% in 2024.
  • Over the past 5 years, Adaptive Biotechnologies' Operating Expenses (Yearly) stood at $251.2 million in 2020, then spiked by 44.63% to $363.3 million in 2021, then increased by 6.11% to $385.5 million in 2022, then rose by 3.07% to $397.3 million in 2023, then fell by 14.05% to $341.5 million in 2024.